

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—CHEDE–8**

Notice is hereby given that, on August 10, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), CHEDE–8 (“CHEDE–8”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Borgwarner Inc., Auburn Hills, MI, and Toyota Industries Corporation, Aichi, JAPAN have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CHEDE–8 intends to file additional written notifications disclosing all changes in membership.

On December 4, 2019, CHEDE–8 filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on December 30, 2019 (84 FR 71977).

The last notification was filed with the Department on April 21, 2020. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on May 6, 2020 (85 FR 26988).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2020–18978 Filed 8–27–20; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Open Source Imaging Consortium**

Notice is hereby given that, on August 19, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Open Source Imaging Consortium, Inc. (“Open Source Imaging Consortium”) has filed

written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Brainomix Ltd., Oxford, UNITED KINGDOM, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Open Source Imaging Consortium intends to file additional written notifications disclosing all changes in membership.

On March 20, 2019, Open Source Imaging Consortium filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on April 12, 2019 (84 FR 14973).

The last notification was filed with the Department on May 18, 2020. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on June 2, 2020 (85 FR 33733).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2020–18983 Filed 8–27–20; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Institute of Electrical and Electronics Engineers**

Notice is hereby given that, on August 4, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), the Institute of Electrical and Electronics Engineers (“IEEE”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 49 new standards have been initiated and 9 existing standards are being revised. More detail regarding these changes can be found at: [https://](https://standards.ieee.org/about/sasb/sba/june2020.html)

standards.ieee.org/about/sasb/sba/june2020.html.

On February 8, 2015, the IEEE Board of Directors approved an update of the IEEE patent policy for standards development, which became effective on 15 March 2015. The updated policy is available at <http://standards.ieee.org/develop/policies/bylaws/approved-changes.pdf> and, from the effective date, will be available at <http://standards.ieee.org/develop/policies/bylaws/sect6-7.html>.

On September 17, 2004, IEEE filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 3, 2004 (69 FR 64105).

The last notification was filed with the Department on May 27, 2020. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on June 26, 2020 (85 FR 38391).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division, Department of Justice.

[FR Doc. 2020–18982 Filed 8–27–20; 8:45 am]

BILLING CODE 4410–11–P

DEPARTMENT OF JUSTICE**Drug Enforcement Administration**

[Docket No. 16–33]

Heavenly Care Pharmacy; Decision and Order

On August 3, 2016, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration issued an Order to Show Cause (“OSC”) to Heavenly Care Pharmacy (hereinafter, Respondent or Respondent Pharmacy), which sought to revoke Respondent’s DEA Certificate of Registration FH4377291, at the registered location of 617 9th Ave., Bessemer, Alabama, and to deny any pending or current applications for renewal or modifications of FH4377291. Administrative Law Judge Exhibit (ALJX) 1 (OSC), at 1–2, 7 (citing 21 U.S.C. 823(f), 824(a)(4)). The OSC alleged that Respondent’s continued registration is inconsistent with the public interest. *Id.* at 1. Specifically, the OSC alleged that Respondent (1) failed to exercise its corresponding responsibility to assess the legitimacy of prescriptions that it filled in violation of 21 CFR 1306.04(a) and failed to dispense controlled substances within the bounds of the pharmacy profession in violation of 21 CFR 1306.06, *id.* at 2; (2) failed to maintain certain records required under federal and Alabama